Gwynn Douglas Long, MD

Professor of Medicine
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address gwynn.long@duke.edu

1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors.
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.

Education and Training

  • Fellow in Medical Oncology, Medicine, Stanford University, 1987 - 1990
  • Medical Resident, Medicine, Vanderbilt University, 1983 - 1986
  • M.D., Wake Forest University, 1983
  • M.S., Wake Forest University, 1979

Publications

Rizzieri, D. A., J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, et al. “Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support..” J Clin Oncol 17, no. 10 (October 1999): 3064–74. https://doi.org/10.1200/JCO.1999.17.10.3064.

PMID
10506601
Full Text

Shpall, E. J., C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, et al. “A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients..” Blood 93, no. 8 (April 15, 1999): 2491–2501.

PMID
10194427
Scholars@Duke

Ross, M., G. M. Schmidt, J. C. Niland, M. D. Amylon, A. C. Dagis, G. D. Long, A. P. Nademanee, et al. “Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival..” Biol Blood Marrow Transplant 5, no. 5 (1999): 285–91.

PMID
10534058
Scholars@Duke

Long, G. D., M. D. Amylon, K. E. Stockerl-Goldstein, R. S. Negrin, N. J. Chao, W. W. Hu, A. P. Nademanee, et al. “Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies..” Biol Blood Marrow Transplant 3, no. 6 (December 1997): 324–30.

PMID
9502300
Scholars@Duke

Hausdorff, J., E. Davis, G. Long, R. Hoppe, M. van der Pas, C. Lassman, O. Kamel, and C. Jacobs. “Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy..” Cancer J Sci Am 3, no. 5 (September 1997): 303–11.

PMID
9327155
Scholars@Duke

Long, G. D. “Renal cell carcinoma..” Curr Opin Oncol 9, no. 3 (May 1997): 301–6.

PMID
9229154
Scholars@Duke

Horning, S. J., N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume. “High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices..” Blood 89, no. 3 (February 1, 1997): 801–13.

PMID
9028311
Scholars@Duke

Kusnierz-Glaz, C. R., P. G. Schlegel, R. M. Wong, J. R. Schriber, N. J. Chao, M. D. Amylon, W. W. Hu, et al. “Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies..” J Clin Oncol 15, no. 1 (January 1997): 18–25. https://doi.org/10.1200/JCO.1997.15.1.18.

PMID
8996120
Full Text

Long, G. D., N. J. Chao, W. W. Hu, R. S. Negrin, R. M. Wong, and K. G. Blume. “High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma..” Cancer 78, no. 12 (December 15, 1996): 2502–9. https://doi.org/10.1002/(sici)1097-0142(19961215)78:12<2502::aid-cncr9>3.0.co;2-l.

PMID
8952558
Full Text

Chao, N. J., P. M. Parker, J. C. Niland, R. M. Wong, A. Dagis, G. D. Long, A. P. Nademanee, et al. “Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease..” Biol Blood Marrow Transplant 2, no. 2 (May 1996): 86–92.

PMID
9118303
Scholars@Duke

Pages